Cardiology in Review · Nov 19, 2026

Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis

By Sebastian SA, Padda I, Almakadma AH et al.

Left atrial appendage occlusion (LAAO) has emerged as an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation. However, the comparative effectiveness and safety of LAAO versus contemporary OAC, particularly direct oral anticoagulants (DOACs), remain uncertain. We performed an updated systematic review and meta-analysis comparing LAAO with OAC, incorporating both vitamin K antagonist– and DOAC-based studies, with prespecified subgroup analyses of DOAC-treated populations and an exploratory analysis in patients with chronic kidney disease. We included 26 studies (6 randomized controlled trials and 20 observational studies) comprising 106,947 participants, with a mean age of 74.2 years. Follow-up ranged from 3 months to 5 years. Compared with DOACs, LAAO was not associated with a statistically significant difference in the primary composite outcome of ischemic stroke, major bleeding, systemic embolism, all-cause mortality, and cardiovascular mortality (hazard ratio 0.71, 95% confidence interval 0.47–1.07; P = 0.09; I ² = 80%). No significant differences were observed in ischemic stroke or major bleeding compared with overall OAC or DOAC therapy. LAAO was nevertheless associated with significantly lower risks of all-cause and cardiovascular mortality compared with both overall OAC and DOAC therapy.

doi.org/10.1097/crd.0000000000001561Interventions

AgingResearch.News